BOSTON, Dec. 7, 2021 /PRNewswire/ — Delix Therapeutics (the “Company”), a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions, today announced a partnership with The National Institute on Drug Abuse (NIDA), a federal scientific research institute under the U.S. Department of Health and Human Services’ National Institutes of Health (NIH)…

Source

Previous articleCybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder
Next articlePsilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies